Published in final edited form as:

J Alzheimers Dis. 2019 ; 71(1): 281–290. doi:10.3233/JAD-190077.

Adverse vascular risk relates to cerebrospinal fluid biomarker evidence of axonal injury in the presence of Alzheimer's disease pathology

Katie E. Osborn, PsyD¹, Jonathan M. Alverio², Logan Dumitrescu, PhD¹, Kimberly R. Pechman, PhD¹, Alzheimer's Disease Neuroimaging Initiative*, Katherine A. Gifford, PsyD¹, Timothy J. Hohman, PhD^{1,3}, Kaj Blennow, MD, PhD^{4,5}, Henrik Zetterberg, MD, PhD^{4,5,6,7}, Angela L. Jefferson, PhD¹

¹Vanderbilt Memory & Alzheimer's Center, Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37212, USA

²Vanderbilt University School of Medicine, Nashville, TN 37232, USA

³Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN 37212, USA

⁴Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden

⁵Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden

⁶Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK

⁷UK Dementia Research Institute at UCL, London, UK

Abstract

Background—Vascular risk factors promote cerebral small vessel disease and neuropathological changes, particularly in white matter where large-caliber axons are located. How Alzheimer's pathology influences the brain's vulnerability in this regard is not well understood.

Objective—Systemic vascular risk was assessed in relation to cerebrospinal fluid concentrations of neurofilament light, a biomarker of large-caliber axonal injury, evaluating for interactions by clinical and protein markers of Alzheimer's disease.

Methods—Among Alzheimer's Disease Neuroimaging Initiative participants with normal cognition (n=117), mild cognitive impairment (n=190), and Alzheimer's disease (n=95), linear regression related vascular risk (as measured by the modified Framingham Stroke Risk Profile) to neurofilament light, adjusting for age, sex, education, and cognitive diagnosis. Interactions were

Submitting and Corresponding Author: Angela L. Jefferson, PhD, Vanderbilt Memory & Alzheimer's Center, 1207 17th Avenue South, Suite 204, Nashville, TN 37212, Phone: 615-322-8676, Fax: 615-343-1302, angela.jefferson@vumc.org.

*Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf

CONFLICT OF INTEREST/DISCLOSURE STATEMENT

The authors have no conflict of interest to report.

assessed by cognitive diagnosis, and by cerebrospinal fluid markers of A β ₄₂, hyperphosphorylated tau, and total tau.

Results—Vascular risk and neurofilament light were not related in the main effect model ($p=0.08$). However, interactions emerged for total tau ($p=0.01$) and hyperphosphorylated tau ($p=0.002$) reflecting vascular risk becoming more associated with CSF neurofilament light in the context of greater concentrations of tau biomarkers. An interaction also emerged for the Alzheimer's disease biomarker profiles ($p=0.046$) where in comparison to the referent 'normal' biomarker group, individuals with abnormal levels of both A β ₄₂ and total tau showed stronger associations between vascular risk and neurofilament light.

Conclusion—Older adults may be more vulnerable to axonal injury in response to higher vascular risk burdens in the context of concomitant Alzheimer's disease pathology.

INTRODUCTION

Modifiable vascular risk factors, such as systolic hypertension [1], diabetes mellitus [2], and smoking [3, 4] are associated with an increased incidence of cognitive impairment and dementia, likely due to effects on cerebral small vessel disease (SVD) contributing to abnormal cognitive aging [5]. Cerebral SVD exists in the majority of pathologically-confirmed dementia cases [6] and disrupts network connectivity [7, 8], conferring cognitive impairment and decline [9]. Longitudinal data from large-scale multicenter collaborations (i.e., the Leukoaraiosis and Disability (LADIS) Study) are increasingly substantiating the role of cerebral SVD and white matter changes in contributing to cognitive and motor declines, depressive symptomatology, and reduction of functional autonomy with aging [10], including clinical manifestation of vascular-related dementia [11].

Cerebral SVD is the most common pathology to co-occur with Alzheimer's disease (AD) [12, 13], lowers the threshold for clinical expression of AD pathology [14], and compromises the efficacy of anti-amyloid therapy [15]. Extant literature has yet to fully establish the extent to which AD and SVD confer disparate versus overlapping pathological cascades, constituting a critical knowledge gap with important implications for identifying effective prevention and treatment targets. Even if SVD and AD represent unique injury pathways, these two disease processes may exacerbate one another and compromise the aging brain in a synergistic manner [13].

Cerebral white matter is particularly vulnerable to ischemic injury from SVD in advanced age [16], but little is known about whether co-occurring AD pathology affects susceptibility to white matter damage, including axonal injury, in response to vascular risk factors. Animal models of compromised cerebrovascular function suggest ischemia promotes diffuse amyloid precursor protein expression [17] and increased A β deposition [18]. Given that A β clearance occurs through vascular-mediated pathways across the blood-brain barrier [19] and through interstitial fluid bulk flow between perivascular basement membranes [20, 21], cerebral SVD may propagate A β deposition by interfering with the integrity of clearance pathways [22], contributing to worse disease trajectory [23, 24]. Progressive degeneration of cholinergic cells in AD can also disrupt regional cerebral blood flow homeostasis [25, 26], increasing susceptibility of the cerebral vasculature to damage [27, 28]. Overall, vascular

risk likely drives cognitive and neurodegenerative changes through non-AD pathways [29] but concomitantly exacerbates AD-related damage once neural injury exists [30].

A current limitation in understanding the implications of SVD is that the cerebral microvasculature is too small to be clearly visualized *in vivo*, thus interfering with prompt diagnosis and intervention [31]. Accordingly, there is a pressing need to better characterize underlying physiological changes related to cerebrovascular disease burden and unhealthy brain aging [31]. Neurofilament light (NFL) is a protein polymer found in large-caliber myelinated axons. Elevated cerebrospinal fluid (CSF) levels of NFL are posited to reflect axonal injury [32] and correlate with white matter damage and clinical severity across neurodegenerative diseases [33–35]. Unlike the mechanistically heterogeneous nature of white matter hyperintensities observed on magnetic resonance imaging (MRI) fluid-attenuated inversion recovery (FLAIR), which correspond to multiple structural changes and pathological processes [36], CSF concentrations of NFL allow for measurement of axonal injury. Accordingly, CSF NFL offers a means of measuring axonal damage in the aging brain. Given the high prevalence of vascular-related health problems among older adults at risk for AD [37], more research is warranted to elucidate how burgeoning AD pathology influences the aging brain's vulnerability to vascular-related damage, including axonal injury. This research topic is especially clinically relevant given the modifiable nature of most vascular risk factors and paucity of promising prevention and treatment targets for AD.

In the current study, we assess how vascular risk burden as measured by the Framingham Stroke Risk Profile (FSRP) relates to axonal injury as measured by CSF NFL in the context of varying degrees of concomitant AD pathology. The FSRP is a composite measure of vascular risk burden. Originally designed to predict incidents of clinical stroke, FSRP scores also correspond to neuroimaging evidence of cerebral SVD, including white matter hyperintensities [38, 39] silent cerebral infarcts [40, 41], and microbleeds [42]. We leveraged the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort, which represents a spectrum from normal cognition (NC), mild cognitive impairment (MCI), and clinical AD. In doing so, we are able to (a) test interactions between FSRP and cognitive diagnosis to determine whether FSRP and NFL associations depend on the presence of clinical symptoms and (b) test interactions between FSRP and AD CSF biomarkers (i.e., A β 42, total tau [t-tau], and hyperphosphorylated tau [p-tau]) to determine how associations differ as a function of co-occurring evidence of AD. Since co-occurring cerebrovascular disease and AD synergistically confer worse clinical outcomes [43, 44], we hypothesize that the association between FSRP and CSF NFL will be strongest with increased AD pathology defined as presence of abnormal concentrations of AD CSF biomarkers (i.e., A β 42, t-tau, and p-tau) and clinical evidence (i.e., stronger associations across cognitive spectrum from NC to clinical AD).

MATERIALS & METHODS

Participants

Participants were drawn from the ADNI, launched in 2003 (<http://adni.loni.usc.edu>). The original ADNI study enrolled approximately 800 participants, aged 55–90 years, excluding major neurological disease (other than AD), and history of brain lesion, head trauma, or

psychoactive medication use (for full inclusion/exclusion criteria, please refer to <http://www.adni-info.org>). Participants were enrolled based on criteria outlined in the ADNI protocol (<http://www.adni-info.org/Scientists>). Specifically, NC participants showed no signs of depression, MCI, or dementia. Participants with MCI presented with subjective memory concerns and impaired performance on Wechsler Memory Scale Logical Memory II in the context of preserved daily living activities and no significant levels of impairment in other cognitive domains nor signs of dementia. Participants with AD met clinical criteria for dementia with a predominantly amnesic profile. Written informed consent was obtained from all participants prior to assessments at each site. Analysis of ADNI's publicly available database was approved by our local Institutional Review Board. We accessed publicly available data from ADNI on 06/09/2017. For the current study, we included participants from the ADNI1 cohort with available baseline CSF biomarker samples and vascular risk factor data necessary to calculate the FSRP.

Vascular Risk Burden

To assess systemic vascular risk burden, we calculated a modified FSRP in the ADNI dataset based on baseline visit data. FSRP assigns points by sex for age, systolic blood pressure (accounting for antihypertensive medication usage), history of diabetes, current cigarette smoking, prevalent cardiovascular disease (i.e., history of myocardial infarction, angina pectoris, coronary insufficiency, intermittent claudication, or heart failure), left ventricular hypertrophy, and history of atrial fibrillation [45]. The FSRP calculation was modified for the current study by excluding left ventricular hypertrophy due to this information being unavailable in ADNI [29, 46].

Lumbar Puncture and Biochemical Analyses

ADNI's CSF protocol, including collection, processing, and storage procedures, have been outlined in detail [47]. We leveraged the master CSF dataset compiled by the University of Pennsylvania (UPENNBIOBK_MASTER) and used the first measure of A β ₄₂, t-tau, and p-tau for each participant. CSF NFL levels were quantified by the Blennow laboratory in Sweden using a sandwich ELISA method (UmanDiagnostics, Sweden) following established procedures [48].

AD Biomarker Profiles

Participants were classified into AD [49] and suspected non-AD pathology (SNAP) [50] biomarker profiles according to A β and t-tau-defined neurodegeneration (ND) status, including biomarker negative (A β -/ND-), amyloid positive only (A β +/ND-), SNAP (i.e., A β -/ND+), and both biomarker positive (A β +/ND+). CSF A β ₄₂ values > 192 pg/mL reflected amyloid positivity, and t-tau values > 93 pg/mL reflected presence of ND based on established cutoffs [51].

Experimental Design and Statistical Analysis

Prior to analyses, six participants were excluded for outlying CSF NFL values (defined as >4 standard deviations). For hypothesis testing, linear regression cross-sectionally related modified FSRP (minus points assigned to age) to CSF NFL concentration (pg/mL),

adjusting for age, sex, education, and cognitive diagnosis (NC, MCI, AD). Next, a series of interaction terms, including (a) *FSRP x cognitive diagnosis*, (b) *FSRP x CSF A β ₄₂*, (c) *FSRP x CSF t-tau*, (d) *FSRP x CSF p-tau*, and (e) *FSRP x AD biomarker profile* were related to CSF NFL in separate models. For interpretive purposes, models were repeated stratifying by cognitive diagnosis, by CSF A β ₄₂ and CSF t-tau using established cutoffs [51], and by AD biomarker profile. Models were not stratified by CSF p-tau due to its established cutoff having relatively poor sensitivity and specificity in distinguishing AD from NC in the ADNI cohort [51]. Significance was set *a priori* at $\alpha=0.05$. Analyses were conducted with R version 3.3.1 (<http://www.r-project.org>).

RESULTS

Participant Characteristics

The sample included 402 adults age 54–89 years (74 ± 7 years), including 117 participants with NC, 190 participants with MCI, and 95 participants with clinical AD. CSF NFL ranged from 405 to 5315 pg/mL. CSF A β ₄₂ ranged from 71 to 300 pg/mL. CSF t-tau ranged from 28 to 495 pg/mL. CSF p-tau ranged from 8 to 115 pg/mL. See Table 1 for participant characteristics by cognitive diagnosis. In this participant sample, CSF NFL weakly correlated with p-tau ($r=0.14$, $p<0.0001$) and total tau ($r=0.23$, $p<0.0001$). CSF NFL and A β ₄₂ were not correlated ($p=0.66$).

FSRP and CSF NFL

See Table 2 for detailed results of main effect, interaction, and stratified analyses. Among the whole sample, FSRP appeared modestly related to NFL, but the association did not meet the *a priori* statistical significance threshold ($\beta=17.97$, $p=0.08$). FSRP did not interact with cognitive diagnosis on NFL levels ($F(2,398)=0.30$; $p=0.74$). In stratified models, FSRP was unrelated to NFL in each of the three diagnostic groups (p -values >0.29).

FSRP interacted with t-tau ($\beta=0.40$, $p=0.01$) and p-tau ($\beta=1.67$, $p=0.002$) on CSF NFL. In stratified models, FSRP was associated with NFL among t-tau positive ($\beta=47.57$, $p=0.002$) but not among t-tau negative participants ($\beta=-0.96$, $p=0.94$). See Fig 1A for illustration. Although the FSRP interaction with amyloid was nonsignificant ($\beta=-0.25$, $p=0.18$), a similar pattern was observed in stratified analyses whereby FSRP was associated with NFL among amyloid positive ($\beta=35.17$, $p=0.006$) but not amyloid negative participants ($\beta=-19.35$, $p=0.24$). See Fig 1B for illustration.

Similar to the continuous biomarker interactions, FSRP interacted with AD biomarker profile ($F(3,389)=2.68$; $p=0.046$). Compared to the A β -/ND- referent group, the A β +/ND+ group differed in the association between FSRP and NFL ($\beta=71.3$, $p=0.005$). No differences were observed between the referent group and the A β +/ND- ($\beta=42.4$, $p=0.10$) or A β -/ND+ ($\beta=55.3$, $p=0.29$) groups. In stratified models, FSRP was associated with NFL in the A β +/ND+ group ($\beta=58.74$, $p=0.002$) but not in the A β -/ND- ($\beta=-32.20$, $p=0.06$), A β +/ND- ($\beta=14.18$, $p=0.49$), or A β -/ND+ ($\beta=30.18$, $p=0.39$) groups. See Fig 2 for illustration.

DISCUSSION

We evaluated associations between FSRP, a comprehensive index of vascular risk, and axonal injury among community-dwelling older adults ranging from cognitively normal to clinical dementia, assessing for interactions with cognitive diagnosis and CSF measurements of AD pathology. Axonal injury was quantified using CSF NFL, a biomarker posited to reflect large-caliber axon damage [52] that is elevated in MCI [48] and clinical AD [32] and may explain unique variance in clinical manifestation of AD beyond core AD pathology [32]. Within the ADNI cohort, we found the association between vascular risk burden and axonal damage appears amplified by the presence of AD pathology. Specifically, FSRP interacted with both p-tau and t-tau in a manner suggesting that associations with axonal injury became stronger in participants commensurate with their extent of neurofibrillary tangle pathology (p-tau) and neurodegeneration (t-tau). A similar interaction also emerged for AD biomarker profile wherein compared to the referent 'normal' biomarker group, individuals with abnormal levels of both A β ₄₂ (indicating cerebral amyloid deposition) and total tau (indicating neurodegeneration) showed stronger associations between vascular risk and axonal injury. While FSRP did not interact with A β ₄₂ on NFL, stratified analyses indicated a modest association was present within the amyloid positive group. However, these stratified results should be interpreted with caution given the lack of a significant interaction effect.

Older adults may be more vulnerable to axonal injury in response to vascular risk burden when neural integrity is already compromised by the cumulative effects of mounting AD pathology. It is unlikely that tau pathology on its own directly accounts for the stronger association between vascular risk factors and axonal injury since prior work has not consistently supported a link between CSF tau and white matter damage [53], including work from our group investigating white matter macrostructure [36] and microstructure damage [54]. Like NFL, tau is a cytoskeleton protein, but tau differs from NFL in that it promotes microtubule stability and is more abundant in smaller, unmyelinated axons localized predominantly in cortical tissue. In contrast, NFL primarily serves to increase diameter and conduction velocity of large-caliber, myelinated subcortical axons [55, 56]. Compared to tau, NFL appears to have more clinical staging and prognostic utility across brain diseases involving prominent degradation of white matter tracks. For example, CSF concentrations of NFL but not tau differentiate between relapsing-remitting and primary progressive types of multiple sclerosis [57]. CSF concentrations of NFL but not tau also distinguish clinical Huntington disease patients from preclinical gene expansion carrier controls and correlate with 5-year probability of disease onset among the gene expansion carriers [58]. While NFL does not appear to have disease specificity as a marker of axonal injury, its utility in reflecting clinical staging across diseases may convey value as a concomitant biomarker to be studied in conjunction with more disease-specific markers of AD.

The dominant theory of AD pathophysiology posits that biomarkers become abnormal in an ordered but temporally overlapping manner. A long asymptomatic phase of amyloid aggregation eventually reaches a threshold with subsequent progressive neuronal dysfunction and death corresponding to CSF t-tau elevations [59]. Accordingly, elevated t-

tau and p-tau coupled with increased evidence of amyloid aggregation may reflect more advanced AD pathology and neurodegeneration, which could compromise neural resilience to vascular risk burden, resulting in greater vulnerability to axonal injury.

It is noteworthy that cognitive diagnosis did not modify the association between FSRP and NFL, suggesting the link between vascular risk burden and axonal injury occurs in both asymptomatic and symptomatic individuals. This finding has important therapeutic implications, as vascular-related axonal damage in AD may be detectable both prior to and throughout the clinical manifestation of symptoms. Future research should incorporate longitudinal models to further elucidate how vascular-related axonal injury temporally relates to the emergence and progression of AD symptoms.

Collectively, findings from this study suggest presence of vascular risk factors confers a greater likelihood of axonal damage in the context of mounting AD pathology and neurodegeneration, regardless of clinical status. These findings should be interpreted in the context of certain study limitations. The cross-sectional nature of our design limits our ability to draw causal inferences or speculate about temporal ordering of pathological changes or whether specific substrates of the AD pathophysiological cascade drive the observed associations. Unfortunately, gold-standard MRI FLAIR data are unavailable in this particular subset of the ADNI cohort, so white matter hyperintensities and other markers of cerebral SVD could not be examined. Other limitations to consider when interpreting results include that ADNI participants are predominantly non-Hispanic white and well-educated, so findings may not be generalizable to more diverse populations. Furthermore, ADNI eligibility criteria excluded for overt cerebrovascular disease (i.e., Hachinski score ≥ 4), so stroke risk and cerebrovascular pathology are likely underrepresented in the ADNI sample compared to the general population. Even with this study exclusion, we still observed associations between vascular risk burden and axonal injury. We speculate that in a cohort with greater vascular risk factors and cerebral SVD, the associations reported here would be stronger.

Despite these limitations, our study has several strengths, including the large, well-characterized dataset representing the entire cognitive aging spectrum from clinically normal to dementia. This range permitted evaluation of vascular risk and axonal injury in the context of preclinical and clinical AD. Additionally, the FSRP incorporates multiple vascular risk factors, offering a more comprehensive and integrated risk index, as opposed to examining risk factors individually.

Vascular-related axonal injury represents an important potential target for primary prevention and clinical intervention among individuals at high risk for developing AD or in the preclinical stages of AD. Whereas there are no current treatments or preventative therapies for AD, most vascular health problems are preventable or modifiable in nature. Primary prevention and close medical management of vascular health conditions should be emphasized to mitigate the clinical progression of AD in older adults. Further investigation into mechanisms linking vascular risk factors and axonal damage in AD and in non-AD-related abnormal cognitive aging is warranted to examine longitudinal associations and identify possible therapeutic targets.

ACKNOWLEDGMENTS

Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01-AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory of Neuro Imaging at the University of Southern California.

This research was also supported by F32-AG058395 (KEO), R01-HL111516 (ALJ), R01-NS100980 (ALJ), R01-AG056534 (ALJ), R01-AG034962 (ALJ), K24-AG046373 (ALJ), Paul B. Beeson Career Development Award in Aging K23-AG045966 (KAG), K01-AG049164 (TJH), UL1-TR000445 (Vanderbilt Clinical Translational Science Award), S10-OD023680 (Vanderbilt's High-Performance Computer Cluster for Biomedical Research), and the Vanderbilt Memory & Alzheimer's Center.

REFERENCES

- [1]. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A (2001) Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. *BMJ* 322, 1447–1451. [PubMed: 11408299]
- [2]. Ahtiluoto S, Polvikoski T, Peltonen M, Solomon A, Tuomilehto J, Winblad B, Sulkava R, Kivipelto M (2010) Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. *Neurology* 75, 1195–1202. [PubMed: 20739645]
- [3]. Cataldo JK, Prochaska JJ, Glantz SA (2010) Cigarette smoking is a risk factor for Alzheimer's Disease: an analysis controlling for tobacco industry affiliation. *J Alzheimers Dis* 19, 465–480. [PubMed: 20110594]
- [4]. Aggarwal NT, Bienias JL, Bennett DA, Wilson RS, Morris MC, Schneider JA, Shah RC, Evans DA (2006) The relation of cigarette smoking to incident Alzheimer's disease in a biracial urban community population. *Neuroepidemiology* 26, 140–146. [PubMed: 16493200]
- [5]. Breteler MM, van Swieten JC, Bots ML, Grobbee DE, Claus JJ, van den Hout JH, van Harskamp F, Tanghe HL, de Jong PT, van Gijn J, et al. (1994) Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study. *Neurology* 44, 1246–1252. [PubMed: 8035924]
- [6]. Carotenuto A, Rea R, Colucci L, Ziello AR, Molino I, Carpi S, Traini E, Amenta F, Fasanaro AM (2012) Late and early onset dementia: what is the role of vascular factors? A retrospective study. *J Neurol Sci* 322, 170–175. [PubMed: 22967745]
- [7]. Monti MM, Vanhaudenhuyse A, Coleman MR, Boly M, Pickard JD, Tshibanda L, Owen AM, Laureys S (2010) Willful modulation of brain activity in disorders of consciousness. *N Engl J Med* 362, 579–589. [PubMed: 20130250]
- [8]. Bernat JL (2006) Chronic disorders of consciousness. *Lancet* 367, 1181–1192. [PubMed: 16616561]
- [9]. Wijdicks EF, Cranford RE (2005) Clinical diagnosis of prolonged states of impaired consciousness in adults. *Mayo Clin Proc* 80, 1037–1046. [PubMed: 16092583]
- [10]. Pantoni L, Fierini F, Poggesi A (2015) Impact of cerebral white matter changes on functionality in older adults: An overview of the LADIS Study results and future directions. *Geriatr Gerontol Int* 15 Suppl 1, 10–16. [PubMed: 26671152]
- [11]. Verdelho A, Madureira S, Moleiro C, Ferro JM, Santos CO, Erkinjuntti T, Pantoni L, Fazekas F, Visser M, Waldemar G, Wallin A, Hennerici M, Inzitari D (2010) White matter changes and

diabetes predict cognitive decline in the elderly: the LADIS study. *Neurology* 75, 160–167. [PubMed: 20625169]

- [12]. Schneider JA, Arvanitakis Z, Bang W, Bennett DA (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. *Neurology* 69, 2197–2204. [PubMed: 17568013]
- [13]. Attems J, Jellinger KA (2014) The overlap between vascular disease and Alzheimer's disease--lessons from pathology. *BMC Medicine* 12, 206. [PubMed: 25385447]
- [14]. Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, Monsell SE, Kukull WA, Trojanowski JQ (2013) Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. *Brain* 136, 2697–2706. [PubMed: 23842566]
- [15]. Weekman EM, Sudduth TL, Caverly CN, Kopper TJ, Phillips OW (2016) Reduced Efficacy of Anti-Abeta Immunotherapy in a Mouse Model of Amyloid Deposition and Vascular Cognitive Impairment Comorbidity. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 36, 9896–9907. [PubMed: 27656027]
- [16]. Baltan S (2009) Ischemic injury to white matter: an age-dependent process. *Neuroscientist* 15, 126–133. [PubMed: 19307420]
- [17]. Pluta R (2000) The role of apolipoprotein E in the deposition of beta-amyloid peptide during ischemia-reperfusion brain injury. A model of early Alzheimer's disease. *Annals of the New York Academy of Sciences* 903, 324–334. [PubMed: 10818522]
- [18]. Aliev G, Smith MA, de la Torre JC, Perry G (2004) Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer's disease. *Mitochondrion* 4, 649–663. [PubMed: 16120422]
- [19]. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV (2000) Clearance of Alzheimer's amyloid-ss(1–40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. *The Journal of clinical investigation* 106, 1489–1499. [PubMed: 11120756]
- [20]. Weller RO (1998) Pathology of cerebrospinal fluid and interstitial fluid of the CNS: significance for Alzheimer disease, prion disorders and multiple sclerosis. *Journal of neuropathology and experimental neurology* 57, 885–894. [PubMed: 9786239]
- [21]. Weller RO, Massey A, Kuo YM, Roher AE (2000) Cerebral amyloid angiopathy: accumulation of A beta in interstitial fluid drainage pathways in Alzheimer's disease. *Annals of the New York Academy of Sciences* 903, 110–117. [PubMed: 10818495]
- [22]. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M (1996) beta-Amyloid-mediated vasoactivity and vascular endothelial damage. *Nature* 380, 168–171. [PubMed: 8600393]
- [23]. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM (2003) Silent brain infarcts and the risk of dementia and cognitive decline. *The New England Journal of Medicine* 348, 1215–1222. [PubMed: 12660385]
- [24]. Dobbie S, Bombois S, Bruandet A, Delbeuck X, Lepoittevin S, Delmaire C, Leys D, Pasquier F (2007) Subcortical hyperintensities are associated with cognitive decline in patients with mild cognitive impairment. *Stroke* 38, 2924–2930. [PubMed: 17885256]
- [25]. Peruzzi P, von Euw D, Lacombe P (2000) Differentiated cerebrovascular effects of physostigmine and tacrine in cortical areas deafferented from the nucleus basalis magnocellularis suggest involvement of basalocortical projections to microvessels. *Ann N Y Acad Sci* 903, 394–406. [PubMed: 10818530]
- [26]. Blin J, Ivanoiu A, Coppens A, De Volder A, Labar D, Michel C, Laterre EC (1997) Cholinergic neurotransmission has different effects on cerebral glucose consumption and blood flow in young normals, aged normals, and Alzheimer's disease patients. *Neuroimage* 6, 335–343. [PubMed: 9417975]
- [27]. Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. *Nature Reviews. Neuroscience* 12, 723–738. [PubMed: 22048062]
- [28]. Fernando MS, Simpson JE, Matthews F, Brayne C, Lewis CE, Barber R, Kalaria RN, Forster G, Esteves F, Wharton SB, Shaw PJ, O'Brien JT, Ince PG (2006) White matter lesions in an

unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. *Stroke* 37, 1391–1398. [PubMed: 16627790]

- [29]. Hohman TJ, Samuels LR, Liu D, Gifford KA, Mukherjee S, Benson EM, Abel T, Ruberg FL, Jefferson AL, Initiative AsN (2015) Stroke risk interacts with Alzheimer's disease biomarkers on brain aging outcomes. *Neurobiology of Aging* 36, 2501–2508. [PubMed: 26119224]
- [30]. Villeneuve S, Reed BR, Madison CM, Wirth M, Marchant NL, Kriger S, Mack WJ, Sanossian N, DeCarli C, Chui HC, Weiner MW, Jagust WJ (2014) Vascular risk and Aβ interact to reduce cortical thickness in AD vulnerable brain regions. *Neurology* 83, 40–47. [PubMed: 24907234]
- [31]. Smith EE, Beaudin AE (2018) New insights into cerebral small vessel disease and vascular cognitive impairment from MRI. *Curr Opin Neurol* 31, 36–43. [PubMed: 29084064]
- [32]. Skillback T, Farahmand B, Bartlett JW, Rosen C, Mattsson N, Nagga K, Kilander L, Religa D, Wimo A, Winblad B, Rosengren L, Schott JM, Blennow K, Eriksdotter M, Zetterberg H (2014) CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. *Neurology* 83, 1945–1953. [PubMed: 25339208]
- [33]. Norgren N, Sundstrom P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M (2004) Neurofilament and glial fibrillary acidic protein in multiple sclerosis. *Neurology* 63, 1586–1590. [PubMed: 15534240]
- [34]. Shahim P, Tegner Y, Gustafsson B, Gren M, Arlig J, Olsson M, Lehto N, Engstrom A, Hoglund K, Portelius E, Zetterberg H, Blennow K (2016) Neurochemical Aftermath of Repetitive Mild Traumatic Brain Injury. *JAMA Neurol* 73, 1308–1315. [PubMed: 27654934]
- [35]. Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, Giovannoni G, Fratta P, Sidle K, Fish M, Orrell R, Howard R, Talbot K, Greensmith L, Kuhle J, Turner MR, Malaspina A (2015) Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. *Neurology* 84, 2247–2257. [PubMed: 25934855]
- [36]. Osborn KE, Liu D, Samuels LR, Moore EE, Cambrero FE, Acosta LMY, Bell SP, Babicz MA, Gordon EA, Pechman KR, Davis LT, Gifford KA, Hohman TJ, Blennow K, Zetterberg H, Jefferson AL (2018) Cerebrospinal fluid β-amyloid42 and neurofilament light relate to white matter hyperintensities. *Neurobiology of Aging* 68, 18–25. [PubMed: 29702372]
- [37]. National Center for Health S (2007) Health, United States In Health, United States, 2007: With Chartbook on Trends in the Health of Americans National Center for Health Statistics (US), Hyattsville (MD).
- [38]. Jeerakathil T, Wolf PA, Beiser A, Massaro J, Seshadri S, D'Agostino RB, DeCarli C (2004) Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study. *Stroke* 35, 1857–1861. [PubMed: 15218158]
- [39]. Smith PJ, Blumenthal JA, Babyak MA, Watkins LL, Hinderliter A, Hoffman BM, Steffens DC, Sherwood A, Doraiswamy PM (2010) Cerebrovascular risk factors and cerebral hyperintensities among middle-aged and older adults with major depression. *Am J Geriatr Psychiatry* 18, 848–852. [PubMed: 20808104]
- [40]. Delgado P, Riba-Llena I, Tovar JL, Jarca CI, Mundet X, Lopez-Rueda A, Orfila F, Llusa J, Manresa JM, Alvarez-Sabin J, Nafria C, Fernandez JL, Maisterra O, Montaner J (2014) Prevalence and associated factors of silent brain infarcts in a Mediterranean cohort of hypertensives. *Hypertension* 64, 658–663. [PubMed: 24958500]
- [41]. Das RR, Seshadri S, Beiser AS, Kelly-Hayes M, Au R, Himali JJ, Kase CS, Benjamin EJ, Polak JF, O'Donnell CJ, Yoshita M, D'Agostino RB Sr., DeCarli C, Wolf PA (2008) Prevalence and correlates of silent cerebral infarcts in the Framingham offspring study. *Stroke* 39, 2929–2935. [PubMed: 18583555]
- [42]. Ochi N, Tabara Y, Igase M, Nagai T, Kido T, Miki T, Kohara K (2009) Silent cerebral microbleeds associated with arterial stiffness in an apparently healthy subject. *Hypertens Res* 32, 255–260. [PubMed: 19262493]
- [43]. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR (1997) Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. *Journal of American Medical Association* 277, 813–817.
- [44]. Rossi R, Geroldi C, Bresciani L, Testa C, Binetti G, Zanetti O, Frisoni GB (2007) Clinical and neuropsychological features associated with structural imaging patterns in patients with mild

cognitive impairment. *Dementia & Geriatric Cognitive Disorders* 23, 175–183. [PubMed: 17220628]

- [45]. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB (1994) Stroke risk profile: Adjustment for antihypertensive medication. The Framingham Study. *Stroke* 25, 40–43. [PubMed: 8266381]
- [46]. Jefferson AL, Hohman TJ, Liu D, Haj-Hassan S, Gifford KA, Benson EM, Skinner JS, Lu Z, Sparling J, Sumner EC, Bell S, Ruberg FL (2015) Adverse vascular risk is related to cognitive decline in older adults. *Journal of Alzheimer's Disease* 44, 1361–1373.
- [47]. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. *Annals of Neurology* 65, 403–413. [PubMed: 19296504]
- [48]. Zetterberg H, Skillback T, Mattsson N, Trojanowski JQ, Portelius E, Shaw LM, Weiner MW, Blennow K (2016) Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. *JAMA Neurology* 73, 60–67. [PubMed: 26524180]
- [49]. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr., Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & Dementia* 7, 280–292.
- [50]. Jack CR Jr., Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, Kantarci K, Gunter JL, Senjem ML, Ivnik RJ, Roberts RO, Rocca WA, Boeve BF, Petersen RC (2012) An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. *Ann Neurol* 71, 765–775. [PubMed: 22488240]
- [51]. Jagust W, Landau S, Shaw L, Trojanowski J, Koeppe R, Reiman E, Foster N, Petersen R, Weiner M, Price J (2009) Relationships between biomarkers in aging and dementia. *Neurology* 73, 1193–1199. [PubMed: 19822868]
- [52]. Petzold A (2005) Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. *J Neurol Sci* 233, 183–198. [PubMed: 15896809]
- [53]. Jonsson M, Zetterberg H, van Straaten E, Lind K, Syversen S, Edman A, Blennow K, Rosengren L, Pantoni L, Inzitari D, Wallin A (2010) Cerebrospinal fluid biomarkers of white matter lesions - cross-sectional results from the LADIS study. *Eur J Neurol* 17, 377–382. [PubMed: 19845747]
- [54]. Moore EE, Hohman TJ, Badami F, Pechman KR, Gordon EA, Acosta LMY, Bell SP, Babicz MA, Gifford KA, Anderson AW, Blennow K, Zetterberg H, Jefferson AL (In press) Elevated cerebrospinal fluid neurofilament light levels are associated with compromised white matter integrity among older adults. *Neurobiology of Aging*.
- [55]. Friede RL, Samorajski T (1970) Axon caliber related to neurofilaments and microtubules in sciatic nerve fibers of rats and mice. *The Anatomical Record* 167, 379–387. [PubMed: 5454590]
- [56]. Goedert M (1993) Tau protein and the neurofibrillary pathology of Alzheimer's disease. *Trends in Neurosciences* 16, 460–465. [PubMed: 7507619]
- [57]. Perry JE, Churchill LR, Kirshner HS (2005) The Terri Schiavo case: legal, ethical, and medical perspectives. *Ann Intern Med* 143, 744–748. [PubMed: 16287796]
- [58]. Cummings JL (1993) Frontal-subcortical circuits and human behavior. *Archives of neurology* 50, 873–880. [PubMed: 8352676]
- [59]. Jack CR Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ (2013) Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. *Lancet Neurol* 12, 207–216. [PubMed: 23332364]

A. FSRP and CSF NFL by Total Tau Status

B. FSRP and CSF NFL by Amyloid Status

Fig 1. FSRP and CSF NFL Stratified by Biomarker Status.

Solid lines reflect unadjusted values of CSF NFL concentration (Y axis, pg/mL) corresponding to modified FSRP score excluding points assigned for age (X axis). Shading reflects 95% confidence interval. Amyloid positive=CSF $A\beta_{42}$ < 193 pg/mL; amyloid negative=CSF $A\beta_{42}$ $\geq$ 193 pg/mL; t-tau positive=t-tau $\geq$ 93 pg/mL; t-tau negative=t-tau < 93 pg/mL; CSF=cerebrospinal fluid, FSRP=Framingham Stroke Risk Profile, NFL=neurofilament light, t-tau=total tau.

Fig 2. FSRP and CSF NFL by Alzheimer's Disease and Suspected Non-AD Pathophysiology (SNAP) Profile.

Solid lines reflect unadjusted values of CSF NFL concentration (Y axis, pg/mL) corresponding to modified FSRP score excluding points assigned for age (X axis). Shading reflects 95% confidence interval; CSF=cerebrospinal fluid, FSRP=Framingham Stroke Risk Profile, NFL=neurofilament light.

Table 1.**Participant Characteristics**

	NC n=117	MCI n=190	AD n=95	p-value
Age, years	76±5	75±7	75±8	0.28
Sex, % female	48	33	43	0.03^a
Race, % White Non-Hispanic	91	94	98	0.09
Education, years	16±3	16±3	15±3	0.06
<i>APOE</i> -ε4, % carrier	25	55	69	<0.001^{abc}
Modified FSRP, total [*]	12.8±3.2	12.3±4.0	12.8±4.2	0.91
Systolic blood pressure, mmHg	133±17	134±18	135±15	0.56
Anti-hypertensive medication usage, %	54	48	57	0.31
Diabetes mellitus, %	5	5	3	0.77
Current cigarette smoking, %	39	41	46	0.57
Prevalent CVD, %	3	6	4	0.41
Atrial fibrillation, %	1	1	0	0.68
CSF NFL, pg/mL	1120±450	1405±636	1631±764	<0.001^{abc}
CSF Aβ ₄₂ , pg/mL	206±55	165±54	144±41	<0.001^{abc}
CSF t-tau, pg/mL	70±30	103±61	122±58	<0.001^{abc}
CSF p-tau, pg/mL	25±15	36±18	41±20	<0.001^{abc}
Biomarker Group				
Aβ-/ND-, %	54	24	6	<0.001^{abc}
Aβ+/ND-, %	27	31	29	0.79
Aβ+/ND+, %	10	43	61	<0.001^{abc}
Aβ-/ND+, %	9	2	3	0.02^a

Note. Values denoted as mean±standard deviation or percentage.

^{*} Modified FSRP excludes points assigned for left ventricular hypertrophy. Modified FSRP minus age points for each diagnostic group were NC 5.9±2.8, MCI 5.9±2.9 and AD 6.2±2.7.

^a NC differed from MCI, p<0.05;

^b MCI differed from AD, p<0.05;

^c NC differed from AD, p<0.05.

AD=Alzheimer's disease; APOE=apolipoprotein E; CSF=cerebrospinal fluid; CVD=cardiovascular disease; FSRP=Framingham Stroke Risk Profile; MCI=mild cognitive impairment; NC=normal cognition; ND=neurodegeneration; NFL=neurofilament light; p-tau=hyperphosphorylated tau; t-tau=total tau.

Table 2.

Main Effect, Interaction, and Sub-group Analyses of FSRP on NFL

	β	95% Confidence Interval	t-value	F-value	p-value
*Covariates +					
FSRP	17.97	−1.93, 37.87	1.78	--	0.08
FSRP x diagnosis[†]	--	--	--	0.30	0.74
NC	13.58	−12.97, 40.12	1.01	--	0.31
MCI	14.85	−14.54, 44.23	1.00	--	0.32
AD	28.97	−26.13, 84.07	1.04	--	0.30
FSRP x Aβ₄₂	−0.25	−0.62, 0.12	−1.35	--	0.18
A β ₄₂ positive	35.17	10.42, 59.93	2.80	--	0.006
A β ₄₂ negative	−19.35	−51.98, 13.27	−1.17	--	0.24
FSRP x T-tau	0.40	0.09, 0.71	2.53	--	0.01
T-tau positive	47.57	17.23, 77.91	3.10	--	0.002
T-tau negative	−0.96	−27.87, 25.95	−0.07	--	0.94
FSRP x P-tau	1.67	0.59, 2.74	3.05	--	0.002
FSRP x Biomarker Group[†]	--	--	--	2.68	0.046
A β −/ND−	−32.20	−65.11, 0.72	−1.94	--	0.06
A β +/ND−	14.18	−26.72, 55.08	0.69	--	0.49
A β +/ND+	58.74	21.30, 96.17	3.12	--	0.002
A β −/ND+ (SNAP)	30.18	−45.28, 105.65	0.91	--	0.39

Note.

* Covariates include age, sex, education, and cognitive diagnosis.

[†] ANOVA; all other models presented are linear regression analyses.

CSF=cerebrospinal fluid; FSRP=Framingham Stroke Risk Profile; MCI=mild cognitive impairment; NC=normal cognition; ND=neurodegeneration; NFL=neurofilament light; P-tau=hyperphosphorylated tau; SNAP=suspected non-AD pathology; T-tau=total tau.